As of today, Formycon AG (ISIN DE000A1EWVY8) is listed in the Prime Standard on the Frankfurt Stock Exchange, the segment with the highest transparency requirements. Previously, the shares were traded via the open market (Scale segment) in Frankfurt.
To mark the listing of Formycon AG, an opening bell ceremony was held in the morning with representatives of the company on the trading floor in Frankfurt. Following the segment change, the shares can still be traded via the trading venues Xetra and Börse Frankfurt. Specialist on the trading venue Börse Frankfurt is Wolfgang Steubing AG Wertpapierdienstleister.
According to its own information, Formycon is a biotechnology company founded in Munich in 2012 with a focus on the development of biopharmaceutical follow-on products, so-called biosimilars. In the first half of 2024, the company generated sales of around EUR 26.9 million.
